VivoSim Labs, Inc. - Common Stock (NQ:VIVS)
Price and Volume
Detailed Quote| Volume | 2,658,117 |
| Open | 0.1819 |
| Bid (Size) | 0.1575 (100) |
| Ask (Size) | 0.1580 (2,700) |
| Prev. Close | 0.1770 |
| Today's Range | 0.1531 - 0.1819 |
| 52wk Range | 0.1495 - 3.400 |
| Shares Outstanding | 8,716,953 |
| Dividend Yield | N/A |
Top News
More News
Performance
52-Week Range
95.3% below 52-week high
0.1594
0.1552W Low
3.4052W High
1 Week
13.7% below 1-week high
0.151W Low
0.181W High
VivoSim Labs, Inc. - Common Stock (VIVS) traded between $0.15 and $3.40 over the past 52 weeks and last traded at $0.16, 95.3% below its 52-week high. Over the past week it ranged between $0.15 and $0.18.
Past 12 Months
+1.6%
-32.3%
-64.6%
-89.2%
-91.5%
-93.0%
1W
+$0.00
1M
-$0.08
3M
-$0.29
6M
-$1.32
YTD
-$1.72
1Y
-$2.13
VIVS was -93.0% over the past year, -89.2% over six months, -91.5% year to date, +1.6% in the last week.
12 Months vs Market
VIVS
-93.0%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%
Over the past 12 months VIVS returned -93.0% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.
Volume & Liquidity
0.94× 3-mo avg
Today 2,658,117
3-mo avg 2.8M
1W
1.4M
1M
881.1K
3M
2.8M
6M
3.1M
YTD
2.4M
1Y
2.0M
VIVS most recently traded 2,658,117 shares against a 3-month average daily volume of 2.8M.
More News
Read More
Via AB Newswire
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via AB Newswire
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
September 28, 2026
Via AB Newswire
Topics
Artificial Intelligence
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026
Via AB Newswire
Via AB Newswire
Topics
Government
Via AB Newswire
Topics
Animal Testing
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026
Via AB Newswire
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
September 14, 2026
Via AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
September 10, 2026
Via AB Newswire
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
September 02, 2026
Via AB Newswire
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
September 01, 2026
Via AB Newswire
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 01, 2026
From VivoSim Labs, Inc.
Via GlobeNewswire
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
September 01, 2026
Via AB Newswire
Topics
Artificial Intelligence
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
August 26, 2026
Via AB Newswire
Topics
Artificial Intelligence
Via AB Newswire
Topics
Artificial Intelligence
VivoSim Provides Financial and Listing Compliance Update
August 06, 2026
From VivoSim Labs, Inc.
Via GlobeNewswire
Via Chartmill
Frequently Asked Questions
Is VivoSim Labs, Inc. - Common Stock publicly traded?
Yes, VivoSim Labs, Inc. - Common Stock is publicly traded.
What exchange does VivoSim Labs, Inc. - Common Stock trade on?
VivoSim Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for VivoSim Labs, Inc. - Common Stock?
The ticker symbol for VivoSim Labs, Inc. - Common Stock is VIVS on the Nasdaq Stock Market
What is the current price of VivoSim Labs, Inc. - Common Stock?
The current price of VivoSim Labs, Inc. - Common Stock is 0.1594
When was VivoSim Labs, Inc. - Common Stock last traded?
The last trade of VivoSim Labs, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of VivoSim Labs, Inc. - Common Stock?
The market capitalization of VivoSim Labs, Inc. - Common Stock is 1.39M
How many shares of VivoSim Labs, Inc. - Common Stock are outstanding?
VivoSim Labs, Inc. - Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>